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S6Ks isoforms contribute to viability,
migration, docetaxel resistance and tumor
formation of prostate cancer cells
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Abstract
Background: The S6 Kinase (S6K) proteins are some of the main downstream effectors of the mammalian Target
Of Rapamycin (mTOR) and act as key regulators of protein synthesis and cell growth. S6K is overexpressed in a
variety of human tumors and is correlated to poor prognosis in prostate cancer. Due to the current urgency to
identify factors involved in prostate cancer progression, we aimed to reveal the cellular functions of three S6K
isoforms–p70-S6K1, p85-S6K1 and p54-S6K2–in prostate cancer, as well as their potential as therapeutic targets.
Methods: In this study we performed S6K knockdown and overexpression and investigated its role in prostate
cancer cell proliferation, colony formation, viability, migration and resistance to docetaxel treatment. In addition,
we measured tumor growth in Nude mice injected with PC3 cells overexpressing S6K isoforms and tested the
efficacy of a new available S6K1 inhibitor in vitro.
Results: S6Ks overexpression enhanced PC3-luc cell line viability, migration, resistance to docetaxel and tumor
formation in Nude mice. Only S6K2 knockdown rendered prostate cancer cells more sensitive to docetaxel.
S6K1 inhibitor PF-4708671 was particularly effective for reducing migration and proliferation of PC3 cell line.
Conclusions: These findings demonstrate that S6Ks play an important role in prostate cancer progression,
enhancing cell viability, migration and chemotherapy resistance, and place both S6K1 and S6K2 as a potential
targets in advanced prostate cancer. We also provide evidence that S6K1 inhibitor PF-4708671 may be considered
as a potential drug for prostate cancer treatment.
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Background
Prostate cancer is the second most frequently diagnosed
cancer among men worldwide and the first in developed
countries [1]. Although prostate cancer has a good
prognosis in its early stages, with nearly all men living at
least five years after diagnosis, the 5-year survival rate
decreases drastically, to less than 30 %, when it reaches
advanced and metastatic stages. This reveals the current
urgency to identify factors involved in prostate cancer
progression [2].
The S6K proteins are members of the AGC family of
serine/threonine kinases and one of the main down-
stream effectors of the mammalian Target Of Rapamycin
(mTOR) protein. In mammals, the S6K family is com-
posed of several proteins encoded by two different
genes: RPS6KB1 and RPS6KB2. Due to the alternative
use of AUG start codons, each S6K gene generates two
distinct isoforms: p70-S6K1, p85-S6K1, p54-S6K2 and
p56-S6K2 [3, 4]. More recently, it has been discovered
that the splicing factor SF2/ASF acts on S6K1 gene
promoting the expression of a novel isoform, p31-S6K1,
that lacks most of its catalytic domain [5]. Once acti-
vated by mTOR, the S6K proteins are able to phospho-
rylate targets as rpS6 (ribosomal protein S6), eIF4B
(eukaryotic translation Initiation Factor 4B) and eEF2K
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(eukaryotic Elongation Factor 2 Kinase), promoting pro-
tein synthesis and cell growth [3].
Due to their key role in regulating cell growth and pro-
liferation, several studies have shown that S6K genes are
amplified in a variety of human tumors, including pros-
tate cancer [6–9]. In fact, S6K is not only overexpressed
in prostate cancer, but also is related to its progression
[10], making it a potential target for prostate cancer
treatment. Despite the high homology shared between
S6K1 and S6K2, evidence shows that they might play
some distinct cellular functions [11]. Global expression
profiles for breast tumors harboring high levels of S6Ks
recently revealed that only a few set of genes strongly
correlated to both S6K1 and S6K2, suggesting that each
protein play different functions in tumorigenesis and
cancer progression [12]. However, these differences have
been poorly investigated and the major understanding
about S6Ks roles in cancer is from studies restricted to
p70-S6K1 [13–19].
Here, we aimed to reveal the cellular functions of three
S6K isoforms–p70-S6K1, p85-S6K1 and p54-S6K2–in
prostate cancer, as well as their potential as therapeutic
targets. We show that all isoforms were important for
increasing prostate cancer cells proliferation, migration
and resistance to docetaxel in vitro. Moreover, S6Ks pre-
sented an important effect for tumor progression in vivo.




Human metastatic prostate cancer cell line PC-3 and the
luciferase expressing cell line PC3-luc were cultured in
Ham’s F12 (Thermo Scientific) supplemented with 10 %
FBS (fetal bovine serum) and 1 % penicillin/streptomycin
(Thermo Scientific). Human metastatic prostate cancer
cell line DU-145 was cultured in Dulbecco’s Modified
Eagle Medium (Thermo Scientific) supplemented with
10 % FBS and 1 % penicillin/streptomycin (Thermo Sci-
entific). Cells were maintained at 37 °C in a humidified at-
mosphere containing 5 % carbon dioxide.
Transfection of human cells
Cells were seeded 24 h before transfection. Transfection
was performed with Lipofectamine and PLUS reagents
(Thermo Scientific). Briefly, DNA and PLUS reagent
were diluted in serum free medium and incubated for
15 min at room temperature. Lipofectamine was then
diluted in serum free medium, mixed to the DNA solu-
tion and incubated for 15 min at room temperature. The
cells were washed with serum free medium and the
DNA/Lipofectamine complexes were added. After 3 h,
the medium was exchanged for medium containing 10 %
FBS and the cells incubated for 24 to 72 h.
Virus production
Lentivirus and retrovirus preparations were generated at
Viral Vector Laboratory, Brazilian National Laboratory for
Biosciences, Brazilian Center for research in Energy and
Materials. Virus were titrated by puromycin selection and
counting forming colonies.
S6Ks RNAi knockdown and overexpression
Lentiviruses expressing shRNA targeting S6K1 and S6K2
human mRNA were produced using pLK0.1 vector (Sigma
Aldrich). S6K1 shRNA sequence (TRCN0000022904) has
been published before [20]. For S6K2 knockdown, we
tested two different shRNA sequences: TRCN0000010539
and TRCN0000199878, identified respectively as shRNA-
S6K2-1 and shRNA-S6K2-2. For the control, we used a
pLKO.1 plasmid (SHC002) that targets no mammalian
genes and was identified as shC.
The retroviral plasmid pBABE-puro was used to perform
S6K overexpression. Fragments of S6K isoforms were
cloned into BamHI/SalI restriction sites and retroviral-
mediated gene transfer was performed as described pre-
viously [21, 22].
Viral transduction
PC3-luc cells were seeded at a density of 8 × 103 cells/well
in 96-well plates and incubated for 24 h. Virus particles
were added at a low multiplicity of infection (MOI) of 0.3
for lentiviruses and 0.1 for retroviruses in the presence of
8 μg/ml of polybrene. Cell culture medium was changed
24 h after transduction and cells were then selected with
1 μg/mL of puromycin until complete death of control
cells.
Western blotting
Proteins were separated by SDS-PAGE and transferred
onto nitrocellulose membranes. Nitrocellulose membranes
were blocked in a solution of TBS containing 5 % nonfat
dry milk and 0,1 % Tween-20 for 2 h with constant agita-
tion. After blocking, the membranes were incubated with
anti-p70-S6K1 (Cell Signaling), anti-S6K2 (Bethyl) or anti-
α-tubulin (Calbiochem) antibodies overnight at 4 °C. Mem-
branes were washed with TBS-T (3 times for 15 min) and
incubated with horseradish peroxidase-conjugated second-
ary antibodies (Millipore) for 1 h at room temperature with
constant agitation. Bands were visualized using the ECL kit
(GE Healthcare). Band densitometry was measured using
ImageJ software.
MTT viability assay
PC3-luc cells with stable S6K knockdown or overexpres-
sion were seeded at a density of 104 cells/well in 96-well
plates and incubated for 24, 48 and 72 h. Following each
period of incubation, 12 mM of 3-(4, 5-methylthiazol-
2-yl)-2, 5-diphenyl-tetrazolium bromide (MTT) was
Amaral et al. BMC Cancer  (2016) 16:602 Page 2 of 9
added to each well for 4 h. The culture medium was aspi-
rated and the formazan crystals were solubilized with a
solution of HCl 1 N:isopropanol (1:25) for 15 min. The
optical density of the plates was measured at 570 nm.
Migration assay
PC3-luc cells with stable S6K knockdown or overexpres-
sion were seeded at a density of 5 × 105 cells/well in 24-
well plates and incubated until confluence. After that, cell
monolayers were scratched in the middle of the wells with
a p200 pipette tip and the culture medium was replaced
by serum free media [23]. Scratch area was analyzed under
light microscope and images were captured right after the
scratch (0 h) and after incubation for 24 and 48 h. The
scratch area was quantified using ImageJ software.
Colony-forming assay
Cells were plated at low density (5 × 102 cells / plate) in
60 mm plates and transfected with plasmids pFLAG-
p70-S6K1, - p85-S6K1, - p54-S6K2 or pFLAG (empty
vector). The cells were incubated at 37 ° C for 10 days.
For staining, the cells were washed with PBS and stained
with 1 mL of methylene blue dye (3 %) for 30 min. The
plates were washed and colonies were counted, exclud-
ing colonies smaller than 1 mm in diameter.
Proliferation assay
Cells were plated in 24-well plates, transfected with plas-
mids pFLAG- p70-S6K1, - p85-S6K1, - p54-S6K2 or
pFLAG (empty vector) and then incubated for up to
6 days with 10 % FBS at 37 ° C. Counts were performed
using automated cell counter on days 2, 4 and 6 after
transfection.
Docetaxel resistance assay
Docetaxel resistance assay was performed as previously
described by Uzoh et al. [24], with slight modifications.
PC3-luc cells with stable S6K knockdown or overexpres-
sion were seeded at a density of 8 × 105 cells/well in 24-
well plates and incubated for 24 h. The culture medium
was then replaced by serum free media and the plates
were incubated for 24 h. Afterwards, cells were treated
with 30 nM of docetaxel (Sigma Aldrich) for 48 h, which
was firstly dissolved in DMSO and then diluted in serum
free media. Control cells received serum free media and
the vehicle. The number of living cells was counted using
an automated cell counter (Thermo Scientific) after Try-
pan Blue staining.
In vivo tumor formation assay
All animal experiments were performed in accordance to
the internal committee of ethics in animal research of the
Faculty of Medicine of the University of São Paulo. One
million PC3-luc cells with stable S6K overexpression or
knockdown were injected subcutaneously into 7 male
athymic Nude mice per group. Tumor growth was mea-
sured about three times per week using a caliper rule and
calculated according to the formula: ½ × (larger diam-
eter) × (smaller diameter) 2 until they reached the max-
imum volume of 1000 mm3.
Treatment of cells with PF4708671
PC3 and DU145 cells were treated with 10 μM of S6K1
inhibitor PF4708671 [25], by changing medium containing
the drug every day, until 6 days. The drug was first
dissolved in DMSO and then diluted in medium with
serum.
Statistical analysis
Values presented are means ± standard deviation (SD).
Statistical analyzes were assessed by one-way and two-way
analysis of variance (ANOVA) followed by Bonferroni’s
post-test and performed using GraphPadPrism 5 software.
p-values < 0.05 were considered significant (*p < 0.05;
**p < 0.01; ***p < 0.001).
Results
S6K knockdown inhibits cell viability
S6Ks stable knockdown and overexpression in PC3-luc
cells were confirmed by western blotting (Fig. 1 a-b).
Although some reports indicate that the knockout of one
S6K isoform in vivo may cause a compensatory upregula-
tion of the other [26, 27], we observed a slight compensa-
tory effect by S6K1 in the S6K2-1 knockdown in vitro. To
investigate the effects of S6Ks knockdown or overexpres-
sion in PC3-luc prostate cancer cell line viability, we
performed the MTT assay. S6K2 knockdown significantly
reduced cell viability in all time periods (Fig. 1c). Similar
inhibition was observed in both S6K2 shRNA sequences
tested. S6K1 knockdown showed significant reduction
only on the second day and appeared to be less relevant
than S6K2. However, the overexpression of all three S6K
isoforms significantly raised cell viability (Fig. 1d).
S6K knockdown inhibits cell migration
Next we investigated if S6K isoforms also impacted the
migration capacity of prostate cancer cells (Fig. 2). Both
S6K1 and S6K2 knockdown resulted in a significant de-
crease in cell migration. Again, no difference was observed
between both S6K2 shRNA sequences. In contrast, as
expected, the overexpression of S6K isoforms significantly
increased scratch area closure.
S6K2 expression is related to docetaxel sensitivity
We investigated whether S6Ks might play a role in pros-
tate cancer chemotherapy resistance. We treated PC3-luc
with docetaxel, a chemotherapeutic drug widely used in
hormone-refractory prostate cancer treatment [28]. As
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Fig. 1 S6Ks increase cell viability in PC3-luc cells. Western blotting analyses of S6K isoforms expression modulation in human prostate cancer cell
line PC3-luc transduced with a lentiviruses pLKO.1-shRNAs against S6K1 and S6K2 and b with retroviruses carrying pBABE construction. S6K1
antibody detects both p85-S6K1 and p70-S6K1 proteins. c Relative cell viability in PC3-luc cells with knockdown of S6Ks isoforms and d in
PC3-luc cells overexpressing S6Ks isoforms. Cells were seeded in 96-well plates at a density of 104 cells/well. After 24, 48 and 72 h, cells
were treated with MTT (12 mM) for 4 h and absorbance was measured at 570 nm. *p < 0.05, **p < 0.01, ***p < 0,001, n = 3
Fig. 2 S6Ks increase migration of PC3-luc cells. Cells were seeded in 24-well plates at a density of 5x104 cells/well and incubated until confluence.
A scratch was made in the cells monolayer with a pipette tip and cells were washed and incubated in serum free media. The scratch area was
measured at 0 (time of scratch), 24 and 48 h. a Migration assay in PC3-luc cells with knockdown of S6Ks isoforms. a, b Scratch relative area of
PC3-luc cells overexpressing S6Ks isoforms. c, d Representative images of scratch area taken at 0, 24 and 48 h of PC3-luc cells with S6K
knockdown and overexpression, respectively. *p < 0.05, **p < 0.01, ***p < 0,001, n = 3
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expected, docetaxel treatment reduced the number of liv-
ing cells in all groups when compared to untreated cells
(Fig. 3). However, the reduction was significantly greater
in cells with S6K2 knockdown (Fig. 3a). When overex-
pressed, all S6Ks isoforms showed significantly less reduc-
tion in the number of living cells than the GFP control
(Fig. 3b).
S6K overexpression enhances tumor growth in Nude mice
After having determined that S6Ks are involved in some
prostate cancer features in vitro, we investigated their
tumorigenic ability in vivo, by injecting PC3-luc cells over-
expressing S6K isoforms or knocked down for S6K1 or
S6K2 subcutaneously into the flanks of male athymic Nude
mice and measuring tumor growth. Tumors started grow-
ing about 10 days after injection and from this moment
tumor volume was assessed for about 30 days. Animals
injected with PC3-luc cells overexpressing S6K isoforms,
particularly p70-S6K1, showed significantly greater tumor
growth than those injected with cells harboring GFP con-
trol (Fig. 4a). Conversely, animals injected with PC3-luc
cells containing the knockdown of S6K1 or S6K2 presented
significantly reduced tumor growth in vivo (Fig. 4b).
S6K1 inhibitor PF47086701 decreases proliferation and
migration of PC3 prostate cancer cell line
To check the efficiency of S6K1 inhibitor in prostate
cancer cells DU145 and PC3, western blotting was per-
formed in order to evaluate the S6 phosphorylation status
(Fig. 5a). Rapamycin was used in this experiment as con-
trol. PF47086701 was able to reduce S6 phosphorylation
in both DU145 and PC3 cells lines, although its effect was
more discrete when compared to rapamycin, which com-
pletely abolished S6 phosphorylation (Fig. 5a). In a proli-
feration assay, DU145 and PC3 cells were plated and
counted after treatment with PF47086701 (10 μM). Only
PC3 cells showed a decrease in the number of cells when
treated with the inhibitor of S6K1 (Fig. 5b). In a migration
assay, the scratched monolayers were treated with serum-
free medium and PF4708671 (10 μM) daily. The areas
were measured within 48 h after the scratch. PC3 cells
showed a significant decrease in migration compared to
control in the presence of S6K1 inhibitor (Fig. 5c).
To compare the effects of S6Ks overexpression in
DU145 and PC3 cell lines, we transiently transfected them
with pcDNA-FLAG vector carrying p70-S6K1, p85-S6K2
and p54-S6K2 genes (Additional file 1: Figure S1A). The
results show that in both cell lines p85-S6K1 isoform
enhanced the cellular proliferation (Additional file 1:
Figure S1B). Colony formation assay also indicated that
cells with overexpression of p85-S6K1 showed increased
number of colonies (Additional file 1: Figure S1C). These
results point an important role of S6K1 isoform in prostate
cancer.
Discussion
S6K proteins are well known effectors of mTOR and major
regulators of protein synthesis and cell growth [4]. They
are found overexpressed in several human tumors and are
correlated with poor prognosis [10, 29, 30]. It has already
been reported that silencing mTOR decreases prostate
cancer cell proliferation and colony formation [31]. Here
we show that S6Ks overexpression enhances proliferation
and clonogenic ability of human metastatic prostate cancer
cell lines. Next, we evaluated the effects of S6K knockdown
and overexpression on prostate cancer cells viability,
migration and resistance to decetaxel treatment.
Recently, Du et al. (2014) showed that mTOR knock-
down by lentivirus mediated shRNA significantly reduces
cell viability in prostate cancer metastatic cell lines LNCaP
and C4-2B. As expected, we not only observed that S6K
knockdown produced similar effects on PC3-luc cells, but
also reported an expressive increase in cell viability deter-
mined by S6K overexpression. Interestingly, we found that
although the effects of p70-S6K1 and p54-S6K2 over-
expression were quite similar, S6K1 knockdown had no
impact on cell viability. A possible explanation is that S6K1
knockdown is compensated by S6K2 isoform, masking the
effects on cell viability.
Fig. 3 p54-S6K2 knockdown increases cell death in response to docetaxel in PC3-luc cells. Cells were seeded in 24-well plates at a density of
8x104 cells/well. After 24 h, cells were subjected to serum free media conditions for 24 h and then treated for 48 h with docetaxel (30 nM).
Living cells were counted and expressed as percentages. Results presented are means of two independent experiments. Each experiment
was performed in triplicates. SMF: serum free media; DTX: docetaxel. *p < 0.05, **p < 0.01, ***p < 0,001, n = 2
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We also reported that S6K expression is positively
related to an increase in PC3-luc cells migration. Since
tumor cell motility is a fundamental part of the metastatic
cascade, our data imply an involvement of all S6K iso-
forms in raising metastatic capability of PC3-luc cells. In
fact, p70-S6K1 has been described as a regulator of cell
motility [32] and several human tumorigenic cell lines,
such rhabdomyosarcoma (Rh1 and Rh30), breast cancer
(MDA-MB-468) and cervical adenocarcinoma (HeLa) were
shown to alter their motility and invasion capabilities in
response to rapamycin and these phenomena were regu-
lated by mTOR through S6K1 and 4E-BP1 [33]. p70-S6K1
can directly bind to F-actin and is localized at the actin
arc of migrating cells [34, 35]. In ovarian cancer cells,
p70-S6K1 regulates cytoskeleton organization and cell
migration by activating the GTPases Rac1 and Cdc42,
involved, respectively, in dictating forward movement and
migration’s direction [34]. Indeed, p70-S6K1 knockdown
ovarian cancer cells migrate less and exhibit reduced
directional persistence [34]. Our results show that S6K1
promotes cell migration in PC3-luc cell line and that
S6K2 is also involved in the regulation of this process.
S6K2 knockdown was also effective in raising docetaxel
sensitivity in PC3-luc cells. It has been reported that S6K2
is activated by FGF-2 (Fibroblast Growth Factor-2) and
phosphorylates PDCD4, a repressor of the translation of
anti-apoptotic proteins such as XIAP and Bcl-xL [36].
PDCD4 phosphorylation by S6K2 causes its degradation
and leads to survival and chemoresistance in lung cancer
cells [36, 37]. Although studies relating S6Ks to chemo-
therapy resistance are scarce, several reports indicate that
mTOR is involved in drug resistance against chemothe-
rapy [38–43]. Niu et al. [44] showed that mTOR inhibition
by rapamycin raises apoptosis and sensitivity to docetaxel
induced cytotoxity in several human metastatic lung can-
cer cell lines treated with different concentrations of doce-
taxel. Treatment with NVP-BEZ235-a PI3K/mTOR dual
inhibitor–was able to sensitize human castration resistant
prostate cancer cell lines C4-2 and C4-2AT6 resistant to
docetaxel, indicating that mTOR inhibition can even
overcome chemoresistance in castration resistant prostate
cancer [45]. However, the specific role of mTOR in deve-
loping chemotherapy resistance is still poorly understood,
yet of current clinical importance. Here, we show that
docetaxel resistance in PC3-luc cell line may be at least in
part mediated by S6K, especially p54-S6K2.
The oncogenic role of S6K was also confirmed in vivo.
The overexpression of all S6K isoforms was able to en-
hance tumor formation in Nude mice and the knockdown
of S6Ks isoforms was able to reduce tumor growth in vivo.
This result corroborates to Du et al. [31], that demon-
strated that Nude mice injected with human metastatic
prostate cancer cell line C4-2B with mTOR knockdown
presented a greater reduction in tumor volume when
compared to control group. As it was shown that p70-
S6K1 played a major role in increasing tumor formation in
vivo, we decided to test the effectiveness of a novel S6K1
inhibitor, PF-4708671.
We demonstrated that targeting S6K1 with PF-4708671
provided reduced cell migration and proliferation in PC3
cells, but had no effect on DU145 cell line (Fig. 5). A
possible explanation for this difference is that PC3 cells,
but not DU145, are PTEN null. PTEN deletion leads to
increased PI3K activity and therefore hyperactivation of
mTORC1/S6K [46]. Thus, it is possible that the mecha-
nisms inducing proliferation and migration in PC3 cells
are more related to S6K activity than in DU145 cells and,
therefore, more susceptible to PF-4708671 effect.
PF-4708671 is a cell-permeable piperazinyl-pyrimidine
compound that specifically inhibits p70-S6K1 with a Ki of
20 nM and IC50 of 160 nM and exhibits no significant
inhibition of S6K2 or other AGC kinases [25], which may
explain the reduced effect to abolish S6 phosphorylation
comparing to rapamycin (Fig 5a), since S6K2 may still act
on S6 protein. Due to its recent development, there are
only a few reports regarding PF-4708671 use in anti-
Fig. 4 S6K isoforms increase tumor growth in Nude mice. a Tumor
growth curves of Nude mice injected subcutaneously with PC3-luc
cells overexpressing S6K isoforms (p70-S6K1, p85-S6K1 and p54-S6K2)
or GFP control. Tumors measurements began 14 days after injection
and proceeded until day 44. b Tumor growth curves of Nude mice
injected subcutaneously with PC3-luc cells with knockdown for S6K1
and S6K2 isoforms or shRNA control. Tumors measurements began
11 days after injection and proceeded until day 39. * p < 0,05,
** p < 0,01 e *** p < 0,001; n = 7
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cancer therapies [3, 25]. S6K1 inhibition by PF-4708671
was shown to sensitize resistant colorectal cancer cells to
selumetinib [47], to decrease cell migration and invasion
of MDA-MB-231 human breast cancer cell line [48] and
to inhibit cell invasion and proliferation in human lung
cancer cell lines and tumorigenesis in Nude mice [49].
Hence, our results ratify that PF-4708671 might be a novel
potential adjuvant in metastatic prostate cancer drug
treatment.
Conclusions
In summary, our study demonstrated that S6K over-
expression enhances cell viability, migration and resistance
to docetaxel in PC3-luc prostate cancer cell line and
tumor volume in Nude mice. In addition, we showed that
the often neglected S6K2 is also involved in these pro-
cesses and might be a potential target to restore docetaxel
sensitivity in advanced prostate cancer. The S6K1 inhibi-
tor PF-4708671 was particularly effective in reducing cell
migration of PC3 and DU145 cell lines, suggesting that it
could represent a possible adjuvant to prevent prostate
cancer progression to its advanced state.
Additional file
Additional file 1: Figure S1. Transient overexpression of different S6Ks
isoforms in DU145 and PC3 cell lines. (A) Western blotting analysis of
transfection efficiency. (B) Proliferation assay in DU145 and PC3 cell lines
transfected with p70-S6K1, p85-S6K1 and p54-S6K2. (C) Colony formation
assay of DU145 and PC3 cells transfected with p70-S6K1, p85-S6K1 and
p54-S6K2. *p < 0.05, **p < 0.01, ***p < 0,001, n = 3. (TIF 2571 kb)
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